Innovent Biologics (HKG:1801) terminated its agreement to issue and sell over 12.8 million new series Pre-A preferred shares of Fortvita Biologics to Lostrancos Ventures following the feedback from its shareholders, a Sunday Hong Kong bourse filing said.
The company had agreed to issue and sell the said shares to the purchaser for $20.5 million on Oct. 25 in order to increase its international business.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。